Humana Stock Climbs 2% Premarket After Wells Fargo Upgrades Shares to Overweight

Humana (NYSE: HUM) shares rose nearly 2% in premarket trading on Monday after Wells Fargo upgraded the health insurer to *Overweight* from *Reduce*, reflecting growing confidence in the company's earnings outlook and recovery prospects.

Why Is Humana Stock Rising Today?

The primary catalyst behind Monday's premarket gain was Wells Fargo's significant rating upgrade, moving Humana directly from Reduce to Overweight.

The upgrade suggests the investment bank believes the company's risk-reward profile has improved following a challenging period for the managed care industry, with recent headwinds increasingly reflected in the stock's valuation.

Medicare Advantage Recovery Boosts Sentiment

Humana has spent the past year navigating higher medical costs and reimbursement pressure within the Medicare Advantage market, factors that weighed heavily on earnings expectations across the health insurance sector.

However, investor sentiment has improved as insurers have adjusted pricing, refined plan offerings, and implemented cost-control measures aimed at restoring profitability. The market is also becoming more optimistic that earnings pressure from elevated medical utilization could moderate over the coming quarters.

Despite Monday's premarket gain, Humana shares remain below their historical highs, although the stock has staged a strong recovery over recent months.

What Investors Are Watching Next

Investors will closely watch Humana's upcoming quarterly earnings for updates on Medicare Advantage enrollment, medical cost trends, and the company's 2027 outlook. Commentary on reimbursement rates, benefit design, and margin recovery will also be key drivers of investor sentiment.

The Wells Fargo upgrade appears to have improved confidence in Humana's recovery story, helping lift the stock in premarket trading as investors increasingly expect the company to benefit from improving fundamentals across the Medicare Advantage business.

Marathon Petroleum Stock Rises 1.5% Premarket as Jefferies Sets $335 Price Target

Marathon Petroleum (NYSE: MPC) shares gained 1.5% in premarket trading on Monday after Jefferies initiated coverage of the refining giant with a Buy rating and a $335 price target, reinforcing optimism as oil prices climbed on escalating geopolitical tensions in the Middle East.

Why Is Marathon Petroleum Stock Rising Today?

The premarket gain was driven by a combination of bullish analyst sentiment and strengthening energy markets.

Jefferies began coverage of Marathon Petroleum with a Buy rating and a $335 price target, highlighting confidence in the company's refining business, strong cash flow generation, and shareholder return strategy. The target implies further upside from the stock's recent trading levels.

Higher Oil Prices Support Energy Stocks

Energy shares broadly strengthened as Brent crude climbed after renewed military tensions between the United States and Iran raised concerns about potential supply disruptions in the Middle East.

Although refiners can experience mixed effects from higher crude prices, sustained volatility in energy markets often supports investor interest in the sector, particularly for companies with diversified operations and strong refining margins.

Marathon Petroleum remains one of the largest independent refiners in the United States and continues to benefit from its integrated refining network, midstream assets through MPLX, and disciplined capital allocation strategy.

What Investors Are Watching Next

Investors will focus on Marathon Petroleum's upcoming quarterly results for updates on refining margins, fuel demand, and capital returns through dividends and share repurchases. Market participants will also monitor crude oil prices and developments in the Middle East, which could continue influencing sentiment across the energy sector.

The combination of Jefferies' new Buy rating, a $335 price target, and rising oil prices appears to be supporting Marathon Petroleum shares in Thursday's premarket trading.

ResMed Stock Falls 2.5% Premarket After Citi Downgrade Extends Weak One-Year Performance

ResMed (NYSE: RMD) shares fell 2.5% in premarket trading on Thursday after Citi downgraded the medical device maker to *Neutral* from *Buy*, adding to pressure on a stock that has already lost about 21% over the past year.

Why Is ResMed Stock Falling Today?

The immediate catalyst for Thursday's decline was Citi's downgrade, with the investment bank lowering its recommendation to Neutral from Buy after the stock's recent rebound.

While Citi did not signal a deterioration in ResMed's underlying business, the downgrade suggests the firm's upside expectations have become more balanced, prompting investors to take profits following the recent recovery from June lows.

ResMed Faces Valuation and Growth Questions

ResMed remains a global leader in sleep apnea and respiratory care devices, supported by recurring demand for CPAP equipment, masks, and its expanding digital health platform.

However, investor sentiment toward the stock has remained cautious over the past year. Beyond valuation concerns, the market continues to monitor the long-term impact of GLP-1 weight-loss therapies on the sleep apnea market, even though management has repeatedly stated that demand for diagnosis and treatment is expected to remain strong.

The latest analyst downgrade comes as ResMed attempts to recover from a prolonged decline that has left the shares down roughly 21% over the past 12 months.

What Investors Are Watching Next

Investors will focus on ResMed's upcoming earnings report for updates on device sales, recurring mask revenue, gross margins, and guidance. Commentary on demand trends, market share, and the evolving relationship between GLP-1 therapies and sleep apnea treatment will also be closely watched.

While Citi's downgrade weighed on the stock in premarket trading, investors are likely to remain focused on whether ResMed can accelerate earnings growth and regain momentum following its challenging performance over the past year.

Shopify Stock Rises 1.9% Premarket After Jefferies Upgrades Shares to Buy

Shopify (NASDAQ: SHOP) shares gained 1.9% in premarket trading on Thursday after Jefferies upgraded the e-commerce platform provider to *Buy* from *Hold* and set a $160 price target, reflecting increased confidence in the company's long-term growth prospects.

Why Is Shopify Stock Rising Today?

The premarket rally follows Jefferies' bullish analyst action, with the firm arguing that Shopify is well positioned to benefit from continued growth in digital commerce and artificial intelligence-powered shopping tools.

The upgrade from Hold to Buy, along with the new $160 price target, signals that Jefferies sees additional upside in the stock despite Shopify's strong performance over the past month.

AI Commerce and Merchant Growth Support Outlook

Shopify has continued to strengthen its position as one of the world's leading e-commerce platforms by expanding its merchant ecosystem and introducing new AI-powered tools that help businesses automate storefront management, customer engagement, and product discovery.

The company has also been investing in enterprise commerce solutions and international expansion while benefiting from continued growth in gross merchandise volume (GMV). Shopify's focus on AI-driven commerce and merchant productivity has become an increasingly important part of its long-term growth strategy.

What Investors Are Watching Next

Investors will be watching Shopify's upcoming earnings report for updates on revenue growth, merchant additions, GMV trends, and adoption of its AI-powered commerce tools. Continued execution in enterprise solutions and international markets could provide additional catalysts for the stock.

The upgrade from Jefferies reinforces Wall Street's constructive outlook on Shopify, with investors remaining optimistic that continued innovation in AI commerce and expanding merchant adoption will support the company's long-term growth trajectory.

KOSPI Drops Nearly 9% as SK Hynix Selloff Following U.S. ADR Debut Weighs on South Korean Market

South Korea's KOSPI plunged nearly 9% on Monday, extending its recent correction as heavy selling in semiconductor stocks triggered a broad market decline. The selloff was led by SK Hynix, whose shares tumbled more than 15% despite the company's record-breaking U.S. ADR listing last week.

SK Hynix Leads Market Lower After Nasdaq Listing

SK Hynix shares fell sharply in Seoul following the company's blockbuster $26.5 billion U.S. ADR offering, which became one of the largest overseas share sales ever by an Asian company. While the Nasdaq debut was initially well received, investors took profits in the Korean-listed shares and shifted attention to the newly listed U.S. ADRs, putting significant pressure on the stock.

Semiconductor Weakness Drags Down KOSPI

As one of the largest constituents of the KOSPI, SK Hynix's steep decline had an outsized impact on the broader market. Other technology stocks, including Samsung Electronics, also came under pressure as investors reduced exposure to the semiconductor sector.

The selloff pushed the KOSPI below the 7,000 level, with the index suffering one of its sharpest single-day declines in recent months. The weakness reflected not only pressure on chipmakers but also broader risk aversion across Asian markets.

Geopolitical Tensions Add to Selling Pressure

Beyond company-specific factors, renewed conflict in the Middle East added another layer of uncertainty for investors.

Rising oil prices following the escalation between the United States and Iran increased concerns about inflation and global economic growth, prompting investors to reduce exposure to risk assets worldwide. Those macroeconomic concerns amplified the selling pressure already building in South Korea's technology-heavy equity market.

What Investors Are Watching Next

Investors will now closely monitor SK Hynix's upcoming earnings, AI memory demand trends, and developments surrounding its newly listed U.S. ADRs. The performance of major semiconductor companies remains critical for the KOSPI given their significant weighting in the index.

For the broader market, sentiment is likely to remain tied to both global technology stocks and geopolitical developments, with any easing of Middle East tensions or renewed confidence in AI-driven semiconductor demand potentially helping stabilize South Korean equities.

Brent Crude Oil Rises 2.6% as U.S.-Iran Conflict Raises Supply Disruption Fears

Brent crude oil climbed more than 2.5% on Monday, extending its recent rally as escalating tensions between the United States and Iran renewed concerns over global oil supplies. Brent futures traded near $78 per barrel after investors priced in the growing risk of supply disruptions in the Middle East.

Middle East Tensions Drive Oil Higher

The latest gains came after the military conflict between the U.S. and Iran intensified, raising fears that crude exports from the region could be disrupted.

A key concern for energy markets is the Strait of Hormuz, one of the world's most important oil shipping routes. After Iran declared the Strait is closed, geopolitical risk premiums have returned to the oil market as traders prepare for the possibility of further escalation.

Supply Risks Outweigh Demand Concerns

The renewed geopolitical tensions have largely overshadowed concerns about slowing global economic growth and weaker fuel demand.

While investors continue to monitor the outlook for China and other major economies, the immediate focus has shifted toward potential supply shocks. Higher oil prices also reflect increased uncertainty surrounding shipping, insurance costs, and production risks across the Middle East.

The rebound follows several weeks of relatively stable prices, with traders now reassessing the balance between adequate global inventories and rising geopolitical risks.

What Investors Are Watching Next

Oil markets will remain highly sensitive to developments in the Middle East over the coming days. Any escalation that threatens production facilities or shipping routes could push prices higher, while signs of diplomatic progress could quickly remove part of the current geopolitical risk premium.

Beyond geopolitics, investors will also monitor upcoming U.S. inflation data, Federal Reserve expectations, and global demand indicators for additional direction.

For now, concerns over potential supply disruptions stemming from the U.S.-Iran conflict remain the dominant driver of Brent crude, helping lift prices despite ongoing uncertainty about the global economic outlook.

Gold Falls as U.S.-Iran Conflict Fuels Inflation Fears and Higher-For-Longer Fed Expectations

Gold prices fell nearly 1% on Monday, with August COMEX futures dropping below $4,080 per ounce, as escalating tensions between the United States and Iran pushed oil prices higher and shifted investor focus from safe-haven demand to the inflationary consequences of the conflict.

Middle East Conflict Lifts Oil Prices, Pressures Gold

While geopolitical uncertainty typically supports gold, the latest escalation in the Middle East has had the opposite effect.

Renewed military exchanges between the U.S. and Iran, along with concerns over potential disruptions to shipping through the Strait of Hormuz, have driven crude oil prices sharply higher. The prospect of higher energy costs has increased fears that inflation could remain elevated for longer, reducing expectations for easier monetary policy.

Higher Treasury Yields and Stronger Dollar Weigh on Bullion

The inflation outlook has pushed U.S. Treasury yields and the U.S. dollar higher, creating headwinds for gold.

As investors price in a greater likelihood that the Federal Reserve will keep interest rates elevated for longer, the opportunity cost of holding non-yielding assets such as gold has increased. Rising bond yields and a firmer dollar have therefore outweighed gold's traditional appeal as a safe-haven asset.

Markets Turn Attention to U.S. Inflation Data

Investors are now looking ahead to key U.S. economic releases, including inflation data and additional labor market indicators, for clues on the Federal Reserve's next policy move.

A stronger-than-expected inflation reading could reinforce expectations that policymakers will maintain a restrictive stance, potentially extending pressure on gold prices. Conversely, signs that inflation is easing despite higher energy costs could help stabilize the precious metal.

For now, the market remains focused on the inflationary implications of the U.S.-Iran conflict rather than its safe-haven characteristics, leaving gold under pressure despite heightened geopolitical risks.

Nuvectis Pharma (NVCT) Gains in Premarket as Analysts Reaffirm Confidence

Nuvectis Pharma (NASDAQ: NVCT) moved higher in premarket trading on Monday after receiving fresh analyst support, extending positive sentiment toward the clinical-stage oncology company.

Shares rose 1.4% in premarket trading after closing 0.3% higher on Thursday. Roth MKM reiterated its Buy rating on Nuvectis, while UBS initiated coverage with a $33.00 price target.

The analyst actions underscore continued confidence in Nuvectis' long-term potential as it advances its pipeline of targeted cancer therapies. The positive outlook reflects optimism surrounding the company's clinical development strategy and future value creation opportunities.

Nuvectis is focused on developing precision oncology treatments targeting difficult-to-treat cancers, with investors closely monitoring upcoming clinical milestones that could serve as important catalysts.

The combination of a reiterated Buy rating from Roth MKM and a new price target from UBS helped support shares in premarket trading, as investors welcomed additional institutional coverage despite the inherent risks associated with clinical-stage biotechnology companies.

### TSMC (TSM) Rebounds in Premarket After Citigroup Reiterates Buy Rating

Taiwan Semiconductor Manufacturing Co. (NYSE: TSM) rebounded in premarket trading on Monday after Citigroup reiterated its Buy rating on the chipmaker, helping restore investor confidence following Thursday's selloff.

TSMC shares fell 2.3% during Thursday's regular session but gained 2.4% in premarket trading after Citigroup reaffirmed its bullish stance on the stock.

The reiterated Buy rating reflects continued confidence in TSMC's long-term growth prospects as the world's leading contract semiconductor manufacturer. The reaffirmation comes as demand for advanced AI chips and high-performance computing remains a key driver for the company.

TSMC continues to benefit from strong capital spending by leading technology companies developing artificial intelligence infrastructure, with its cutting-edge manufacturing processes positioning the company at the center of the AI semiconductor supply chain.

The premarket rebound suggests investors looked past Thursday's weakness, with Citigroup's positive rating reinforcing expectations that TSMC remains well positioned to capitalize on long-term growth in AI, cloud computing, and advanced semiconductor demand.

Gilead Sciences (GILD) Shares Climb After HSBC Sets $155 Price Target

Gilead Sciences (NASDAQ: GILD) gained 4.2% on Thursday and added another 1.3% in premarket trading on Monday after HSBC initiated coverage on the biopharmaceutical company with a *$155 price target*.

The new price target came as Gilead shares extended their recent rally, reflecting continued investor optimism toward the company's growth prospects across its HIV, oncology, and liver disease portfolios.

The $155 target implies additional upside from Thursday's closing price, suggesting HSBC sees room for further appreciation despite the stock's recent gains. While the rating summary did not disclose the firm's detailed investment thesis, the initiation highlights growing institutional interest in Gilead.

Investor sentiment has also been supported by the company's diversified portfolio, strong cash generation, and continued investment in innovative therapies. Gilead remains focused on expanding its oncology business while maintaining its leadership position in HIV treatments, two areas viewed as key long-term growth drivers.

The combination of Thursday's strong rally and HSBC's new price target kept Gilead in focus as investors continued to favor large-cap pharmaceutical companies with stable earnings and attractive growth opportunities.